—AZR-MD-001 is a Potential First-in-Class Therapy Targeting Meibomian Gland Dysfunction (MGD), the Root Cause of Dry Eye Disease (DED) and Contact Lens Discomfort (CLD)— TEL AVIV, Israel--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results